Buscar
Mostrando ítems 1-10 de 40
SGLT-2 inhibitors for people with type 2 diabetes.
(Elsevier, 2019)
Evidence that sodium-glucose co-transporter-2 inhibitors (SGLT2i) can reduce cardiovascular risk—with trials showing reductions in cardiovascular death, myocardial infarction, and stroke—would suggest they have much to ...
Effects of Dipeptidyl-Peptidase 4 Inhibitor about Vascular Inflammation in a Metabolic Syndrome Model
(Public Library of Science, 2014-09)
Background: In this study, we used vidagliptin(V) to examine the role of the DDP-IV, incretin system component, in the activation of different molecular inflammatory cytokines, NF-kB and VCAM-1 to generate a microenvironment ...
Dipeptidyl peptidase IV inhibitor improves the salivary gland histology of spontaneously diabetic mice
(2013-07-01)
Objectives: The incretin-based therapy might be effective in patients possessing certain levels of preserved pancreatic beta-cells. However, doubts still exist regarding the efficacy of this atment in the recovery of tissues ...
Dipeptidyl peptidase IV inhibitor improves the salivary gland histology of spontaneously diabetic mice
(2013-07-01)
Objectives: The incretin-based therapy might be effective in patients possessing certain levels of preserved pancreatic beta-cells. However, doubts still exist regarding the efficacy of this atment in the recovery of tissues ...
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
(BMJ Publishing Group, 2016)
OBJECTIVES: To examine the association between dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of heart failure or hospital admission for heart failure in patients with type 2 diabetes. DESIGN: Systematic review ...
Circulating Dipeptidyl Peptidase IV Activity Correlates With Cardiac Dysfunction in Human and Experimental Heart Failure
(Lippincott Williams & Wilkins, 2013-09-01)
Background the present study addresses the hypothesis that the activity of dipeptidyl peptidase IV (DPPIV), an enzyme that inactivates peptides that possess cardioprotective actions, correlates with adverse outcomes in ...
Metabolic effects of antidiabetic drugs on adipocytes and adipokine expression
(Wiley-Liss Inc., 2019)
Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats
(Elsevier B.V., 2013-01-05)
The purpose of the current study was to test the hypothesis that the dipeptidyl peptidase IV (DPPIV) inhibitor sitagliptin, which exerts anti-hyperglycemic and anti-hypertensive effects, upregulates GLUT4 translocation, ...